Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Mochida's New 3-Year Management Plan Announced
May 17, 2004
- IMSUT to Study Tailor-made Medicine with Iressa, Glivec
May 17, 2004
- Janssen's "Spend A Day" MR Support Program Found Effective
May 17, 2004
- The 48th Meeting of the Japan College of Rheumatology
May 17, 2004
- Alfresa Aims to Expand Group Membership in SAFE
May 17, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
May 17, 2004
- Takeda, Banyu Hired Over 200 New Graduates in April: PJ Survey
May 17, 2004
- DIAGNOSTIC NEWS IN BRIEF
May 17, 2004
- Listed Wholesalers Increased Hiring of New Graduates: PJ Survey
May 17, 2004
- Annual Business Results
May 17, 2004
- Med Professionals Expect Latest Info on Quality, Efficacy, Safety from MRs: Survey
May 17, 2004
- 1st Qtr Business Results
May 17, 2004
- CPhI Japan 2004 Conference
May 17, 2004
- MEDICAL DEVICE NEWS IN BRIEF
May 17, 2004
- BUSINESS NEWS IN BRIEF
May 17, 2004
- Tie-up with Kowa Could Evolve into Full Integration: Mr Tamura of Nikken Chemicals
May 17, 2004
- BUSINESS NEWS IN BRIEF
May 17, 2004
- WEBSITE NEWS
May 17, 2004
- Korosho, Monkasho Hold Hearings on Clinical Trial Promotion Plan
May 17, 2004
- REGULATORY NEWS IN BRIEF
May 17, 2004
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…